SCHEMBL4791992

SCHEMBL4791992

COC(=O)c1n[nH]c2cc(Cl)ccc12

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 3/20 0.65
KDM4E B2RXH2 3/20 0.63
STAT3 P40763 1/20 0.63
HIF1A Q16665 1/20 0.63
NR4A2 P43354 2/20 0.55
GSK3B P49841 2/20 0.52
ALPL P05186 1/20 0.47
MAPT P10636 2/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47
PAK1 Q13153 1/20 0.45
FLT3 P36888 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GALR3 O60755 1/20 0.44
ABL1 P00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30609861 1.00 MAP2K4 (0.65) MAP2K4KDM4ESTAT3HIF1ANR4A2
SCHEMBL4793264 0.88 KDM4E (0.63) MAP2K4KDM4ESTAT3HIF1ANR4A2
SCHEMBL10262737 0.84 KDM4E (0.66) MAP2K4KDM4EGSK3BALPL
SCHEMBL12788089 0.83 KDM4E (0.65) MAP2K4KDM4ESTAT3HIF1ANR4A2
SCHEMBL17423733 0.83 MAP2K4 (0.52) MAP2K4KDM4ESTAT3HIF1ANR4A2
SCHEMBL11160240 0.82 KMT2A (0.50) MAP2K4KDM4ESTAT3HIF1ANR4A2
SCHEMBL11169705 0.82 KMT2A (0.50) MAP2K4KDM4ESTAT3HIF1ANR4A2
SCHEMBL14574212 0.82 KDM4E (0.63) MAP2K4KDM4ESTAT3HIF1AGSK3B
SCHEMBL16516393 0.82 KDM4E (0.63) MAP2K4KDM4ESTAT3HIF1ANR4A2
SCHEMBL31725376 0.82 MAP2K4 (0.65) MAP2K4KDM4ESTAT3HIF1AALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112805282-A Indazole-carboxamide derivatives and uses thereof 广东东阳光药业有限公司 2021-05-14 CN disclosed
WO-2016007837-A1 CARBONYL LINKED BICYCLIC HETEROARYL ANTIBIOTIC TOLERANCE INHIBITORS SPERO THERAPEUTICS, INC. (US) 2016-01-14 WO disclosed
WO-2016007837-A1 CARBONYL LINKED BICYCLIC HETEROARYL ANTIBIOTIC TOLERANCE INHIBITORS SPERO THERAPEUTICS, INC. (US) 2016-01-14 WO disclosed
CN-104011027-A Use of lonidamine analogs for fertility regulation UNIV KANSAS 2014-08-27 CN disclosed
EP-1937647-A1 CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II Inpharmatica Limited (GB) 2008-07-02 EP disclosed
EP-1585743-B1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER (US) 2007-05-23 EP disclosed
EP-1585743-B1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER (US) 2007-05-23 EP disclosed
WO-2007036727-A1 CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II INPHARMATICA LIMITED (GB) 2007-04-05 WO disclosed
WO-2007036727-A1 CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II INPHARMATICA LIMITED (GB) 2007-04-05 WO disclosed
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS INC. 2006-07-20 US disclosed
US-7053107-B2 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. (US) 2006-05-30 US disclosed
EP-1585743-A1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER INC. (US) 2005-10-19 EP disclosed
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2004-09-30 US disclosed
WO-2004056806-A1 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES PFIZER INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192735-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 MAP2K4 284/4885KDM4E 2405/4885STAT3 195/4885
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 MAP2K4 284/4885KDM4E 2405/4885STAT3 195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.